Inbound Relationships |
Type |
Active |
Source |
Characteristic |
Refinability |
Group |
Orphenadrine citrate adverse reaction |
Causative agent (attribute) |
True |
Orphenadrine citrate (substance) |
Inferred relationship |
Some |
1 |
Orphenadrine citrate allergy |
Causative agent (attribute) |
False |
Orphenadrine citrate (substance) |
Inferred relationship |
Some |
|
Orphenadrine citrate 100 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Orphenadrine citrate (substance) |
Inferred relationship |
Some |
|
Orphenadrine citrate 30mg/mL injection solution ampule |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Orphenadrine citrate (substance) |
Inferred relationship |
Some |
|
Orphenadrine citrate 100mg m/r tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Orphenadrine citrate (substance) |
Inferred relationship |
Some |
|
Acetaminophen + orphenadrine citrate 500mg/50mg caplets |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Orphenadrine citrate (substance) |
Inferred relationship |
Some |
|
Acetaminophen + orphenadrine citrate |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Orphenadrine citrate (substance) |
Inferred relationship |
Some |
|
Orphenadrine citrate |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Orphenadrine citrate (substance) |
Inferred relationship |
Some |
|
Aspirin 385 mg and caffeine 30 mg and orphenadrine citrate 25 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Orphenadrine citrate (substance) |
Inferred relationship |
Some |
|
Aspirin 428 mg and caffeine 30 mg and orphenadrine citrate 25 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Orphenadrine citrate (substance) |
Inferred relationship |
Some |
|
Aspirin 770 mg and caffeine 60 mg and orphenadrine citrate 50 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Orphenadrine citrate (substance) |
Inferred relationship |
Some |
|
Aspirin 856 mg and caffeine 60 mg and orphenadrine citrate 50 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Orphenadrine citrate (substance) |
Inferred relationship |
Some |
|
Aspirin + caffeine + orphenadrine citrate tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Orphenadrine citrate (substance) |
Inferred relationship |
Some |
|
Aspirin + caffeine + orphenadrine citrate |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Orphenadrine citrate (substance) |
Inferred relationship |
Some |
|
Orphenadrine citrate allergy |
Causative agent (attribute) |
False |
Orphenadrine citrate (substance) |
Inferred relationship |
Some |
1 |
Orphenadrine citrate 100 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Orphenadrine citrate (substance) |
Inferred relationship |
Some |
1 |
Orphenadrine citrate 100 mg oral tablet |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Orphenadrine citrate (substance) |
Inferred relationship |
Some |
1 |
Aspirin 385 mg and caffeine 30 mg and orphenadrine citrate 25 mg oral tablet |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
False |
Orphenadrine citrate (substance) |
Inferred relationship |
Some |
1 |
Aspirin 428 mg and caffeine 30 mg and orphenadrine citrate 25 mg oral tablet |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
False |
Orphenadrine citrate (substance) |
Inferred relationship |
Some |
1 |
Aspirin 770 mg and caffeine 60 mg and orphenadrine citrate 50 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Orphenadrine citrate (substance) |
Inferred relationship |
Some |
3 |
Aspirin 770 mg and caffeine 60 mg and orphenadrine citrate 50 mg oral tablet |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
False |
Orphenadrine citrate (substance) |
Inferred relationship |
Some |
3 |
Aspirin 856 mg and caffeine 60 mg and orphenadrine citrate 50 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Orphenadrine citrate (substance) |
Inferred relationship |
Some |
3 |
Aspirin 856 mg and caffeine 60 mg and orphenadrine citrate 50 mg oral tablet |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
False |
Orphenadrine citrate (substance) |
Inferred relationship |
Some |
3 |
Aspirin 385 mg and caffeine 30 mg and orphenadrine citrate 25 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Orphenadrine citrate (substance) |
Inferred relationship |
Some |
3 |
Aspirin 385 mg and caffeine 30 mg and orphenadrine citrate 25 mg oral tablet |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
False |
Orphenadrine citrate (substance) |
Inferred relationship |
Some |
3 |
Aspirin 428 mg and caffeine 30 mg and orphenadrine citrate 25 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Orphenadrine citrate (substance) |
Inferred relationship |
Some |
3 |
Aspirin 428 mg and caffeine 30 mg and orphenadrine citrate 25 mg oral tablet |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
False |
Orphenadrine citrate (substance) |
Inferred relationship |
Some |
3 |
Aspirin 856 mg and caffeine 60 mg and orphenadrine citrate 50 mg oral tablet |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Orphenadrine citrate (substance) |
Inferred relationship |
Some |
2 |
Aspirin 770 mg and caffeine 60 mg and orphenadrine citrate 50 mg oral tablet |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
False |
Orphenadrine citrate (substance) |
Inferred relationship |
Some |
1 |
Orphenadrine citrate 100mg prolonged-release oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Orphenadrine citrate (substance) |
Inferred relationship |
Some |
|
Aspirin 385 mg and caffeine 30 mg and orphenadrine citrate 25 mg oral tablet |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
False |
Orphenadrine citrate (substance) |
Inferred relationship |
Some |
1 |
Aspirin 770 mg and caffeine 60 mg and orphenadrine citrate 50 mg oral tablet |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
False |
Orphenadrine citrate (substance) |
Inferred relationship |
Some |
1 |
Orphenadrine citrate 100 mg oral tablet |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Orphenadrine citrate (substance) |
Inferred relationship |
Some |
1 |
Aspirin 428 mg and caffeine 30 mg and orphenadrine citrate 25 mg oral tablet |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
False |
Orphenadrine citrate (substance) |
Inferred relationship |
Some |
1 |
Aspirin 856 mg and caffeine 60 mg and orphenadrine citrate 50 mg oral tablet |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Orphenadrine citrate (substance) |
Inferred relationship |
Some |
2 |
Aspirin 385 mg and caffeine 30 mg and orphenadrine citrate 25 mg oral tablet |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Orphenadrine citrate (substance) |
Inferred relationship |
Some |
2 |
Aspirin 385 mg and caffeine 30 mg and orphenadrine citrate 25 mg oral tablet |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Orphenadrine citrate (substance) |
Inferred relationship |
Some |
2 |
Aspirin 428 mg and caffeine 30 mg and orphenadrine citrate 25 mg oral tablet |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Orphenadrine citrate (substance) |
Inferred relationship |
Some |
2 |
Aspirin 428 mg and caffeine 30 mg and orphenadrine citrate 25 mg oral tablet |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Orphenadrine citrate (substance) |
Inferred relationship |
Some |
2 |
Aspirin 770 mg and caffeine 60 mg and orphenadrine citrate 50 mg oral tablet |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Orphenadrine citrate (substance) |
Inferred relationship |
Some |
2 |
Aspirin 770 mg and caffeine 60 mg and orphenadrine citrate 50 mg oral tablet |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Orphenadrine citrate (substance) |
Inferred relationship |
Some |
2 |